News | May 11, 2011

Consistent, Controlled Drug Delivery Reported With Rapidly Absorbable Stent Coating

May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference regarding the MiStent Drug-Eluting Coronary Stent System (MiStent DES), an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. The data will be presented in Paris, France May 18 in a presentation titled "MiStent DES: A Novel Third Generation DES with a Fully-Absorbable Coating and Enhanced Drug Delivery Capabilities."

In a porcine coronary model, data show continuous and controlled release of sirolimus, with the MiStent DES coating being eliminated from the stent within 45-60 days, and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott Multi-Link Vision coronary stent at 30 and 90 days in the challenging overlapping stents implant configuration.

Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor Sprint DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.

For more information: www.micell.com

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Overlay Init